The industry’s much talked-about patient-centered approach requires more than lip-service and organizational redesigns. For the patient to emerge center stage in a commercial approach after having languished in the wings for years necessitates a totemic shift on the part of manufacturers that aligns both R&D and marketing in focusing squarely on patient needs to drive positive outcomes- clinical as well as behavioral. The result is a successful product with far greater commercial value in a crowded and highly competitive market. This eBook offers actionable strategies, targeted solutions, and specific directions on how to get there.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.